Literature DB >> 29129177

COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update.

Ian A Yang1, Juliet L Brown2, Johnson George3, Sue Jenkins4, Christine F McDonald5, Vanessa M McDonald6, Kirsten Phillips2, Brian J Smith7, Nicholas A Zwar8, Eli Dabscheck9.   

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and chronic airflow limitation, and is associated with exacerbations and comorbidities. Advances in the management of COPD are updated quarterly in the national COPD guidelines, the COPD-X plan, published by Lung Foundation Australia in conjunction with the Thoracic Society of Australia and New Zealand and available at http://copdx.org.au. Main recommendations: Spirometry detects persistent airflow limitation (post-bronchodilator FEV1/FVC < 0.7) and must be used to confirm the diagnosis.Non-pharmacological and pharmacological therapies should be considered as they optimise function (ie, improve symptoms and quality of life) and prevent deterioration (ie, prevent exacerbations and reduce decline).Pulmonary rehabilitation and regular exercise are highly beneficial and should be provided to all symptomatic COPD patients.Short- and long-acting inhaled bronchodilators and, in more severe disease, anti-inflammatory agents (inhaled corticosteroids) should be considered in a stepwise approach.Given the wide range of inhaler devices available, inhaler technique and adherence should be checked regularly.Smoking cessation is essential, and influenza and pneumococcal vaccinations reduce the risk of exacerbations.A plan of care should be developed with the multidisciplinary team. COPD action plans reduce hospitalisations and are recommended as part of COPD self-management.Exacerbations should be managed promptly with bronchodilators, corticosteroids and antibiotics as appropriate to prevent hospital admission and delay COPD progression.Comorbidities of COPD require identification and appropriate management.Supportive, palliative and end-of-life care are beneficial for patients with advanced disease.Education of patients, carers and clinicians, and a strong partnership between primary and tertiary care, facilitate evidence-based management of COPD. Changes in management as result of the guideline: Spirometry remains the gold standard for diagnosing airflow obstruction and COPD. Non-pharmacological and pharmacological treatment should be used in a stepwise fashion to control symptoms and reduce exacerbation risk.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Guidelines as topic

Mesh:

Substances:

Year:  2017        PMID: 29129177     DOI: 10.5694/mja17.00686

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  42 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  Management of Australian Adults with Bronchiectasis in Tertiary Care: Evidence-Based or Access-Driven?

Authors:  Simone K Visser; Peter T P Bye; Greg J Fox; Lucy D Burr; Anne B Chang; Chien-Li Holmes-Liew; Paul King; Peter G Middleton; Graeme P Maguire; Daniel Smith; Rachel M Thomson; Enna Stroil-Salama; Warwick J Britton; Lucy C Morgan
Journal:  Lung       Date:  2019-11-05       Impact factor: 2.584

Review 3.  Digital health for COPD care: the current state of play.

Authors:  Hang Ding; Farhad Fatehi; Andrew Maiorana; Nazli Bashi; Wenbiao Hu; Iain Edwards
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 4.  COPD and the gut-lung axis: the therapeutic potential of fibre.

Authors:  Annalicia Vaughan; Zoe A Frazer; Philip M Hansbro; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 5.  Pre-hospital and emergency department pathways of care for exacerbations of chronic obstructive pulmonary disease (COPD).

Authors:  Emily Sneath; Denise Bunting; Wayne Hazell; Vivienne Tippett; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

6.  Effect of internet-based self-management on pulmonary function rehabilitation and living quality in patients with chronic obstructive pulmonary disease.

Authors:  Qin Huang; Ping Lin; Jianhui Dang; Lizhen Fu; Lili Ding
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

7.  Diagnosis of the cause of chronic dyspnoea in primary and tertiary care: characterizing diagnostic confidence.

Authors:  Yao C Huang; Olivia R Ferry; Scott C McKenzie; Rayleen V Bowman; Michael Hamilton; Philip J Masel; Kwun M Fong; Ian A Yang
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

8.  Development of the Advancing the Patient Experience in COPD Registry: A Modified Delphi Study.

Authors:  Chelsea L Edwards; Alan G Kaplan; Barbara P Yawn; Janwillem W H Kocks; Lakmini Bulathsinhala; Victoria A Carter; Ku-Lang Chang; Chester Fox; Gokul Gopalan; MeiLan K Han; Maja Kruszyk; Chantal E Le Lievre; Cathy Mahle; Barry Make; Wilson D Pace; Chris Price; Asif Shaikh; Neil Skolnik; David B Price
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

9.  Effect of health locus of control on physical activity in stable patients with chronic obstructive pulmonary diseases.

Authors:  Shojiro Egoshi; Shinichiro Hayashi; Jun Horie; Shuichi Shiranita; Hisashi Watanabe; Futoshi Kawaura; Koichiro Takahashi; Toyoko Asami; Naoko Sueoka-Aragane
Journal:  J Phys Ther Sci       Date:  2021-06-18

10.  Evaluation of the curative effects of Bailing capsules for treating chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.

Authors:  Long Zhang; Yumiao Zhao; Junli Jia; Lisha Huang; Weili Chu; Qinfu Xu; Yanbing Sheng; Aiguo Xu
Journal:  Medicine (Baltimore)       Date:  2021-06-25       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.